What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
Cervical cancer
Disease-specific survival
MRI
Tumor size
Journal
Insights into imaging
ISSN: 1869-4101
Titre abrégé: Insights Imaging
Pays: Germany
ID NLM: 101532453
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
25
03
2022
accepted:
17
05
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Tumor size assessment by MRI is central for staging uterine cervical cancer. However, the optimal role of MRI-derived tumor measurements for prognostication is still unclear. This retrospective cohort study included 416 women (median age: 43 years) diagnosed with cervical cancer during 2002-2017 who underwent pretreatment pelvic MRI. The MRIs were independently read by three radiologists, measuring maximum tumor diameters in three orthogonal planes and maximum diameter irrespective of plane (MAX All MRI tumor size variables (cm) yielded high areas under the tdROC curves (AUCs) for predicting survival (AUC 0.81-0.84) at 5 years after diagnosis and predicted outcome (hazard ratios [HRs] of 1.42-1.76, p < 0.001 for all). Only MAX Among all MRI-derived tumor size measurements, MAX
Sections du résumé
BACKGROUND
BACKGROUND
Tumor size assessment by MRI is central for staging uterine cervical cancer. However, the optimal role of MRI-derived tumor measurements for prognostication is still unclear.
MATERIAL AND METHODS
METHODS
This retrospective cohort study included 416 women (median age: 43 years) diagnosed with cervical cancer during 2002-2017 who underwent pretreatment pelvic MRI. The MRIs were independently read by three radiologists, measuring maximum tumor diameters in three orthogonal planes and maximum diameter irrespective of plane (MAX
RESULTS
RESULTS
All MRI tumor size variables (cm) yielded high areas under the tdROC curves (AUCs) for predicting survival (AUC 0.81-0.84) at 5 years after diagnosis and predicted outcome (hazard ratios [HRs] of 1.42-1.76, p < 0.001 for all). Only MAX
CONCLUSION
CONCLUSIONS
Among all MRI-derived tumor size measurements, MAX
Identifiants
pubmed: 35715582
doi: 10.1186/s13244-022-01239-y
pii: 10.1186/s13244-022-01239-y
pmc: PMC9206052
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105Subventions
Organisme : Helse Vest
ID : F-12512
Organisme : Norwegian research council
ID : 311350
Organisme : Trond Mohn stiftelse
ID : BFS2018TMT06
Informations de copyright
© 2022. The Author(s).
Références
Clin Transl Radiat Oncol. 2019 Jun 15;18:9-15
pubmed: 31341971
BMC Med Res Methodol. 2018 Jul 20;18(1):81
pubmed: 30029629
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Gynecol Cancer. 2018 Oct;28(8):1545-1552
pubmed: 30044321
Cell J. 2019 Jan;20(4):604-607
pubmed: 30124010
Gynecol Oncol. 1999 Aug;74(2):245-51
pubmed: 10419739
Gynecol Oncol. 2013 Jun;129(3):517-21
pubmed: 23528928
Cancer Res Treat. 2020 Apr;52(2):516-523
pubmed: 31671937
J Low Genit Tract Dis. 2016 Oct;20(4):317-20
pubmed: 27438585
Clin Imaging. 2016 Jan-Feb;40(1):72-8
pubmed: 26459788
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Biometrics. 2005 Mar;61(1):92-105
pubmed: 15737082
Gynecol Oncol. 2007 May;105(2):427-33
pubmed: 17275889
Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17
pubmed: 28599900
Stat Med. 2013 Dec 30;32(30):5381-97
pubmed: 24027076
Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):395-404
pubmed: 9308943
Eur J Radiol Open. 2015 Jul 26;2:111-7
pubmed: 26937443
BMC Med Res Methodol. 2017 Apr 7;17(1):53
pubmed: 28388943
Acta Radiol. 2019 Mar;60(3):388-395
pubmed: 29911401
Gynecol Oncol. 2007 Nov;107(2):310-5
pubmed: 17826822
Int J Gynecol Cancer. 2015 Mar;25(3):459-66
pubmed: 25628109
Int J Radiat Oncol Biol Phys. 1992;23(3):491-9
pubmed: 1612949
Eur J Gynaecol Oncol. 2013;34(1):39-41
pubmed: 23589998
Biom J. 2005 Aug;47(4):458-72
pubmed: 16161804
Int J Gynecol Cancer. 2018 May;28(4):641-655
pubmed: 29688967
Radiology. 2013 Oct;269(1):149-58
pubmed: 23788721
Gynecol Oncol. 2017 Dec;147(3):577-584
pubmed: 29110878
Radiat Oncol. 2019 Oct 4;14(1):173
pubmed: 31585543
BJOG. 2004 Jul;111(7):741-7
pubmed: 15198766
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645